Surgical Management and Biology of Peritoneal Metastasis

Send us Fan MailThe suitability of a patient for Cytoreductive Surgery (CRS) combined with Hyperthermic Intraperitoneal Chemotherapy (HIPEC) is determined by a complex interplay of tumor biology, disease distribution, and patient-specific physiological factors.Key determinants include:Tumor Histology and Biology: The primary site and the "grade" of the cancer are critical. Patients with favorable histology, such as low-grade appendiceal mucinous neoplasms, certain colorectal cancers, and ovarian cancers, derive the most significant survival gains. Conversely, patients with high-grade biology or gastric peritoneal metastasis often face poorer outcomes, making aggressive surgery less likely to be beneficial.Disease Burden (Peritoneal Cancer Index): The Peritoneal Cancer Index (PCI) is used to quantify the extent of the disease across 13 regions of the abdomen. A high PCI score often predicts a low probability of achieving a complete cytoreduction. Specifically, extensive involvement of the small bowel or its mesentery is a major contraindication, as removing too much tissue risks "short-bowel syndrome," while leaving disease behind compromises the oncological benefit.Listen in to explore more. Don’t forget to check out out YouTube and Facebook page to enjoy more engaging contents. DISCLAIMER: This content is for reference only and you must follow local/standard guidelines in clinical practiceLike, share and subscribe.  Support the showQuick discussion and review of topics that interests you.